Annals of Oncology 14:1449-1450, 2003
© 2003 European Society for Medical Oncology
Letters to the Editor |
Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline
1 Department of Medical Oncology, 2 Department of Internal Medicine, 3 Department of Urology, 4 Department of Radiology, 5 Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
*E-mail: stakahas@jfcr.or.jp
Malignant pheochromocytomas are rare, accounting for 
10% of all cases of pheochromocytoma. The prognosis is poor because of local recurrence or widespread metastasis [1]. To date, there has been no established chemotherapy for malignant pheochromocytoma. A conventional CVD regimen (consisting of cyclophosphamide, vincristine and dacarbazine) may reduce tumors, but remission is short [2]. Thus, attempts to devise other regimens are warranted in order to obtain a better outcome.
We report a 50-year-old Japanese male who had rapidly progressive malignant pheochromocytoma and was successfully treated with an ACVD regimen, anthracyclines plus CVD. The patient was diagnosed with left adrenal pheochromocytoma (4 x 3 cm) with increased catecholamine (CA) excretion levels and underwent adrenectomy in August 1990. He had become asymptomatic and CA excretion level dropped to normal after the surgery. Six years later, he presented with lower back pain, soaking sweats and right inguinal lymphadenopathy. CAs and their metabolites were elevated (Table 1). A CT (computed tomography) scan showed enlarged lymph nodes in the pelvic and para-aortic region. Biopsy specimens of the inguinal lymph node revealed relapse of the pheochromocytoma. Subsequently, the right inguinal lymph node enlarged from 2 to 10 cm in 2 weeks, and the back pain was aggravated.
|
In February 1996, a combination chemotherapeutic regimen was initiated, consisting of doxorubicin 40 mg/m2 body surface area (BSA) on day 1, cyclophosphamide 750 mg/m2 BSA on day 1, vincristine 1.4 mg/m2 BSA on day 1 and dacarbazine 250 mg/m2 BSA on days 1–5, every 3–4 weeks. On the following day, the blood pressure dropped to 90/56 mm Hg. With i.v. hydration increased, his general condition improved within a few days. Symptoms were resolved over 2 weeks with normalization of CAs and their metabolites (Table 1). Since cardiovascular instability occurred, doxorubicin was replaced with epirubicin, which has lower cardiotoxicity, in the later chemotherapy. The patient was given 12 courses of ACVD combination chemotherapy, which led to a complete remission of the tumor and a biochemical response. Side-effects were grade 1 bone marrow suppression, nausea and hair loss. After February 1997, the consolidation CVD regimen was administered monthly for
3 years. There has been no sign of recurrence for 3 years after the cessation of chemotherapy. Considering their neural crest origin and biological similarities, the chemotherapeutic regimens for neuroblastoma could be promising candidates for malignant pheochromocytoma. The CVD regimen was based on the treatment for advanced neuroblastoma. This regimen has been reported to produce good responses in malignant pheochromocytoma, but the median duration of remission is 21 months [2]. For aggressive neuroblastoma, a combination chemotherapeutic regimen of cyclophosphamide, vincristine, dacarbazine and doxorubicin (CYVADIC) has been suggested to be more effective than doxorubicin alone or combination therapy without doxorubicin (CYVDIC) [3]. We achieved long-lasting complete remission using a ACVD regimen in a case with rapidly progressive disease.
To our knowledge, this is the first report of an anthracycline-containing combination chemotherapy for metastasized malignant pheochromocytoma. The ACVD regimen might be a feasible combination chemotherapy, with monitoring of the cardiovascular system; furthermore, it might improve response rates and lengthen disease-free survival.
M. Nakane1, S. Takahashi1*, I. Sekine2, I. Fukui3, M. Koizumi4, K. Kage2, Y. Ito1, K. Aiba1, N. Horikoshi1, K. Hatake1, Y. Ishikawa5 & E. Ogata2
1Department of Medical Oncology, 2Department of Internal Medicine, 3Department of Urology, 4Department of Radiology, 5Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan (*E-mail: stakahas@jfcr.or.jp)
References
1. van Heerden JA, Sheps SG, Hamberger B et al. Pheochromocytoma: current status and changing trends. Surgery 1982; 91: 367–373.[Web of Science][Medline]
2. Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109: 267–273.
3. Dosik GM, Rodriguez V, Benjamin RS, Bodey GP. Neuroblastoma in the adult: effective combination chemotherapy. Cancer 1978; 41: 56–63.[Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K.-S. Park, J.-L. Lee, H. Ahn, J.-M. Koh, I. Park, J.-S. Choi, Y. R. Kim, T. S. Park, J.-H. Ahn, D. H. Lee, et al. Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 327 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Joshua, S. Ezzat, S. L. Asa, A. Evans, R. Broom, M. Freeman, and J. J. Knox Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 5 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu Pheochromocytoma: Current Approaches and Future Directions Oncologist, July 1, 2008; 13(7): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||